Synthetic drugs and monoclonal antibodies, which can prevent TNF-α-mediated molecular mechanisms, have been approved by the FDA and are currently used in the treatment of diseases such as Crohn’s disease, Psoriatic arthritis, Rheumatoid arthritis, Juvenile idiopathic arthritis, Ankylosing spondylitis, Ulcerative colitis, Uveitis, and Hidradenitis suppurativa [5]. This evidence concerns the gene TNF and ankylosing spondylitis.